{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/25/3317396/0/en/Kymera-Therapeutics-Completes-Enrollment-in-the-Phase-2b-BROADEN2-Trial-of-KT-621-in-Atopic-Dermatitis-with-Topline-Data-by-Year-end-2026.html", "message": "News view counter 816195 successfully enlarged"}